✨ Free AI Report
Editas Medicine, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Editas Medicine, Inc.
Research Preview

Editas Medicine, Inc.: Business Overview, Financials & Competitive Analysis

Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for b...

Analyst-debate audio for Editas Medicine, Inc.

AskCyborg analysts argue the bull and bear cases for Editas Medicine, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Editas Medicine, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Early-stage CRISPR gene editing company with promising preclinical data and strategic partnerships, but significant clinical and...

Read the full analyst-debate transcript →
Industry Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Editas Medicine, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Editas Medicine, Inc. Overview

Pro stress-test →

Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for both systems. The company is a clinical-stage gene editing company focused on in vivo CRISPR-based medicines, positioning itself at the forefront of precision genetic medicine.

Strategic Profile

Pro stress-test →

Editas's lead in vivo development candidate, EDIT-401, is designed as a one-time treatment for hyperlipidemia through LDLR gene editing and has shown substantial LDL-C reductions in preclinical models. The company engages in collaborations, including with Bristol Myers Squibb and Vertex Pharmaceuticals, while advancing its pipeline. Its differentiation lies in proprietary lipid nanoparticle delivery and gene upregulation strategies targeting liver and blood cell therapies.

Competitive Landscape

Pro stress-test →

Editas competes within the gene editing space against Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, Prime Medicine, Fate Therapeutics, Sangamo Therapeutics, Precision BioSciences, and others. The competitive advantage hinges on proprietary CRISPR platform efficiency, delivery mechanisms, and clinical trial success timelines in the nascent field.

Industry Context

Editas Medicine, Inc. operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector.

Key facts

Founded: 2013 · Headquarters: Cambridge, US · Employees: 246 · Revenue: $0.03B · Market cap: $0.21B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Editas Medicine, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Editas Medicine, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CRISPR Gene EditingBase editing and epigenetic modulation→CRISPR Gene EditingIn vivo CRISPR medicine platform→CRISPR Gene EditingZinc finger nuclease genome editing→

Compare Editas Medicine, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Editas Medicine, Inc. operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector. See how the rest of the sector scores on the Cyborg framework.

Browse Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector research →
NEW · MCP server

Ask your AI assistant about Editas Medicine, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Editas Medicine, Inc. and its top competitor on Cyborg Score”
“What did Editas Medicine, Inc. do this quarter?”
“Is Editas Medicine, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Editas Medicine, Inc. do?+
Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for b...
What is Editas Medicine, Inc.'s Cyborg Score?+
Editas Medicine, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Editas Medicine, Inc.'s main competitors?+
Named competitors include CRISPR Gene Editing, CRISPR Gene Editing, CRISPR Gene Editing. The full competitive landscape is in the AskCyborg report.
How can I get the full Editas Medicine, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Editas Medicine, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Editas Medicine, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.